References
- Sackett D L, Richardson W S, Rosenberg W, Haynes R B. Evidence-based medicine: how to practice and teach EBM. Churchill Livingstone, New York 1997; 72
- Ellard J. The music of psychiatry. Australian and New Zealand Journal of Psychiatry 1985; 19: 153–156
- The Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17: 129–146
- Davis D A, Thompson M A, Oxman A D, Haynes R B. Changing physician performance. A systematic review of the effect of continuing medical education strategies. Journal of the American Medical Association 1995; 274: 700–705
- Gilbert P L, Harris M J, McAdams L A, Jeste D V. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry 1995; 52: 173–188
- Jeste D V, Gilbert P L, McAdams L A, Harris M J. Considering neuroleptic maintenance and taper on a continuum. Need for longitudinal rather than dogmatic approach. Archives of General Psychiatry 1995; 52: 209–212
- Davis J M, Kane J M, Marder S R, et al. Dose response of prophylactic antipsychotics. Journal of Clinical Psychiatry 1993; 54(Suppl)24–30
- Letemendia F J, Harris A D, Willems P J. The clinical effects on a population of chronic schizophrenic patients of administrative changes in hospitals. British Journal of Psychiatry 1967; 113: 959–971
- Hirsch S R, Gaind R, Rohde P D, Stevens B C, Wing J K. Outpatient maintenance of chronic schizophrenic patients with long acting fluphenazine: a double-blind placebo trial. British Medical Journal 1973; 1: 633–637
- Hogarty G E, Ulrich R E. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry 1997; 34: 297–301
- Miese U, Fleishaker W. Perceptions on treatment needs in schizophrenia. Brirish Journal of Psychiatry 1996; 168(Suppl. 29)9–16
- American Psychiatric Association. Tardive dyskinesia. American Psychiatric Association, Washington, DC 1992, A task force report of the American Psychiatric Association
- Loebel A D, Leiherman J A, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R. Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry 1992; 149: 1183–1188
- McEvoy J P, Hogarty G E, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 1991; 48: 739–745
- Kopala L C, Fredrikson D, Good K P, Honer W G. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biological Psychiatry 1996; 39: 296–298
- American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry 1997; 154(Suppl. 4)1–61
- The Quality Assurance Project 1984. Treatment outlines for the management of schizophrenia. Australian and New Zealand Journal of Psychiatry 1984; 18: 19–38
- Steering Committee, American Psychiatric Association. The Expert Consensus Guideline Series. Treatment of schizophrenia. Journal of Clinical Psychiatry 1996; 57(Suppl. 12b)1–59
- White P. Identification of randomised clinical trials in the Australian and New Zealand Journal of Psychiatry for the Cochrane Collaboration. Australian and New Zealand Journal of Psychiatry 1996; 30: 531–533